Advertisement
Advertisement

RIGL

RIGL logo

Rigel Pharmaceuticals Inc. (New)

36.69
USD
Sponsored
+0.14
+0.37%
Jun 25, 12:36 UTC -4
Open

RIGL Earnings Reports

Positive Surprise Ratio

RIGL beat 30 of 42 last estimates.

71%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$70.28M
/
$0.92
Implied change from Q1 26 (Revenue/ EPS)
+19.49%
/
+109.09%
Implied change from Q2 25 (Revenue/ EPS)
-30.88%
/
-71.95%

Rigel Pharmaceuticals Inc. (New) earnings per share and revenue

On May 05, 2026, RIGL reported earnings of 0.44 USD per share (EPS) for Q1 26, missing the estimate of 0.69 USD, resulting in a -36.87% surprise. Revenue reached 58.82 million, compared to an expected 63.64 million, with a -7.58% difference. The market reacted with a -5.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 0.92 USD, with revenue projected to reach 70.28 million USD, implying an increase of 109.09% EPS, and increase of 19.49% in Revenue from the last quarter.
FAQ
For Q1 2026, Rigel Pharmaceuticals Inc. (New) reported EPS of $0.44, missing estimates by -36.87%, and revenue of $58.82M, -7.58% below expectations.
The stock price moved down -5.06%, changed from $28.09 before the earnings release to $26.67 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 4 analysts, Rigel Pharmaceuticals Inc. (New) is expected to report EPS of $0.92 and revenue of $70.28M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement